ArticleNeurology and therapy2026
Treatment Preferences for Subcutaneous Immunoglobulin Among Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Caregivers, and Physicians: A Discrete Choice Experiment.
Article in Neurology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSubcutaneous immunoglobulin (SCIG) is a recommended maintenance treatment option for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and could offer greater patient convenience than intravenous immunoglobulin (IVIG). We evaluated the burden of CIDP and assessed the value that patients with CIDP, caregivers, and physicians place on various attributes of SCIG treatment options.
methodsThis was an online discrete choice experiment survey designed through targeted literature review and patient/caregiver/physician interviews, conducted in Germany, the UK, and the USA. The survey was administered to adults with CIDP who were stable on IVIG and/or receiving SCIG, and caregivers/physicians. Participants chose preferred treatment profiles comprising six SCIG treatment attributes with varying levels: chance of CIDP symptom worsening, treatment frequency, number of sites per infusion, time spent on infusion per month, chance of infusion site reaction, and infusion location. Subgroup analyses were also performed. A conditional logistic regression model estimated preference weight for each attribute.
resultsOverall, 146 patients, 52 caregivers, and 81 physicians completed the survey; mean (standard deviation) patient age was 58.1 (12.8) years; time since CIDP diagnosis was 8.8 (9.3) years; 98.6% had received IVIG, and 30.8% had received SCIG. Patients and caregivers experienced a substantial burden of disease that negatively impacted quality of life and work productivity. The most important factors in treatment decision-making were a lower chance of CIDP symptom worsening in 6 months, less frequent treatment administration, and home infusion (all p < 0.001 vs reference categories). Patients considered a lower chance (10% vs 20%) of symptom worsening and lower treatment frequency (every 3-4 weeks vs weekly) as the most important SCIG attributes, accounting for 64.6% of the decision weight.
conclusionThere remains a substantial burden on patients and caregivers due to CIDP. Patients with CIDP highly valued efficacy and convenience when considering preferred SCIG options. Preference awareness may facilitate shared patient-physician decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.